CRISPR-Cas13d gene therapy targeting DUX4

CRISPR-Cas13d gene therapy targeting DUX4 is an experimental, preclinical gene therapy approach being investigated for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a neuromuscular disorder characterized by the toxic expression of the DUX4 gene in skeletal muscle, which leads to progressive muscle wasting. This therapeutic strategy utilizes the CRISPR-Cas13d system—a bacterial-derived, RNA-guided ribonuclease—to specifically target and degrade DUX4 mRNA transcripts. Unlike Cas9-based systems that edit genomic DNA, Cas13d acts at the post-transcriptional level, potentially reducing the risk of permanent off-target genomic alterations. The therapy is designed for delivery via adeno-associated virus (AAV) vectors, using guide RNAs (gRNAs) to direct the Cas13d enzyme to DUX4 transcripts. Preclinical studies have demonstrated significant reduction in DUX4 protein levels and improved histopathological markers in FSHD models.